Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Low affinity immunoglobulin gamma Fc region receptor II-a (FCGR2A, also known as CD32A) is a transmembrane glycoprotein expressed on myeloid cells, including macrophages, monocytes, neutrophils, dendritic cells, and platelets. It functions as an activating Fc receptor that binds the Fc portion of immunoglobulin G (IgG) antibodies and immune complexes, initiating critical immune responses such as phagocytosis, antibody-dependent cellular cytotoxicity (ADCC), and the release of inflammatory cytokines. Structurally, FCGR2A contains an intracellular immunoreceptor tyrosine-based activation motif (ITAM) that recruits Syk kinase upon ligand binding to trigger downstream signaling cascades. Dysregulation of FCGR2A is heavily implicated in autoimmune disorders like systemic lupus erythematosus (SLE) and rheumatoid arthritis, as well as thrombotic conditions such as heparin-induced thrombocytopenia (HIT). Additionally, a common single nucleotide polymorphism (H131R) in FCGR2A significantly alters its binding affinity for IgG subclasses, serving as a key biomarker that predicts patient response to therapeutic monoclonal antibodies like rituximab and cetuximab. Therapeutic strategies targeting FCGR2A include the development of specific antagonists, such as the humanized effector-deficient antibody VIB9600 (MEDI9600), to block immune complex-mediated inflammation without triggering platelet activation or anaphylaxis.
Antagonist, Fc-receptor binding, Receptor internalization
8 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Low affinity immunoglobulin gamma Fc region receptor II-a (FCGR2A).